Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Cellular Therapy, Marrow Toxic Injury. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy. Representatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including: * investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data * evaluating the factors that affect transplant or cellular therapy outcome * studying the distribution of HLA tissue types in different populations * studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries * performing de-linked (anonymous) research
Detailed description
Research samples will be accepted from the following four categories:
* Hematopoietic Cell or other Cellular Therapy Donors * Cord Blood Units * Hematopoietic Cell Transplantation or other Cellular Therapy Recipients * Patients with Marrow Toxic Injury
Primary outcome measures
- To make blood samples available for research studies related to histocompatibility and HCT or other cellular therapy [Time frame: pre-HCT (recipient) or pre-donation (donor)]
Eligibility criteria
Eligibility to participate in the Research Sample Repository Protocol:
Hematopoietic Cell (HC) or Other Cellular Therapy Donors
- Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.
- All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.
Cord Blood Units (CBUs)
- Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.
Hematopoietic Cell Transplantation or Other Cellular Therapy Recipients
- All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.
Patients with Marrow Toxic Injury
- Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.
- Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- NMDP Biorepository — New Brighton
Identifiers
NCT: NCT04920474 · NMDP IRB-1991-0002